Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.
Level 2 - randomized trial
Individual randomized controlled trial (pilot design)
PubMed 36776073 · doi:10.3233/JAD-221238
What was done
In a two-stage, double-blind, randomized, placebo-controlled pilot trial, researchers first enrolled cognitively healthy participants (n = 5; 3 active, 2 placebo) and subsequently patients with mild-to-moderate Alzheimer's disease (n = 11; 5 active, 6 placebo). Participants were assigned 1:1 to receive either daily 40 Hz Invisible Spectral Flicker (ISF) or color- and intensity-matched non-flickering white light placebo (up to 60 minutes per session). The primary objectives were safety and feasibility/adherence, with secondary exploratory endpoints evaluating cognition and MRI-measured hippocampal and ventricular volumes at 6 and 12 weeks.
What was found
Adverse events were few and mild. Treatment adherence exceeded 86.1% of intended days, with participants spending >51.3 minutes in front of the device and maintaining directed gaze for >34.9 minutes. At week 6, cognitive change scores showed a mean of -2.6 (SD 6.58) in the active group versus 1.5 (SD 6.53) in the placebo group, with no early volumetric changes. At week 12, hippocampal volume change was 0.34% (SD 3.26) in the active group versus -2.03% (SD 1.18) in placebo, while ventricular volume change was -0.36% (SD 1.89) in active versus 2.50% (SD 2.05) in placebo.
Why it matters
Visible 40 Hz stroboscopic light can cause discomfort and poor adherence; this study shows that invisible spectral modulation achieves high compliance and acceptable safety in patients with Alzheimer's disease.
Limits
The sample size is extremely small (total n = 16 across two stages; only 11 with Alzheimer's disease), precluding any definitive conclusions on clinical or structural efficacy. Standard deviations were wide, follow-up was limited to 12 weeks, and the specific cognitive testing instruments are not detailed in the abstract.
Cited by
- partial Non-stroboscopic 40 Hz light stimulation from Optoceutics (the EVY light) achieves a 94% adherence rate and produces significant improvements in mood, energy, focus, sleep, and memory.